$13.16
0.08% yesterday
Nasdaq, Nov 14, 10:00 pm CET
ISIN
US08205P1003
Symbol
BNTC

Benitec Biopharma Inc Stock price

$13.16
-1.90 12.62% 1M
-0.42 3.09% 6M
+0.53 4.20% YTD
+2.76 26.54% 1Y
+10.35 368.31% 3Y
-34.10 72.15% 5Y
-895.16 98.55% 10Y
-196.84 93.73% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
+0.01 0.08%
ISIN
US08205P1003
Symbol
BNTC
Industry

Key metrics

Basic
Market capitalization
$442.7m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-41.7m | $-36.2m
EBIT
$-41.8m | $-51.8m
Net Income
$-37.9m | -
Free Cash Flow
$-23.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-88.3% | 13.1%
EBIT
-85.7% | -24.1%
Net Income
-69.5% | -
Free Cash Flow
-20.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-
ROIC
-
Debt/Equity
-
More
EPS
$-0.9
FCF per Share
-
Short interest
10.2%
Employees
16
Rev per Employee
$0.0
Show more

Is Benitec Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,041 stocks worldwide.

Benitec Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Benitec Biopharma Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Benitec Biopharma Inc forecast:

Buy
93%
Hold
7%

Financial data from Benitec Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 27 27
286% 286%
-
- Research and Development Expense 27 27
72% 72%
-
-42 -42
88% 88%
-
- Depreciation and Amortization 0.07 0.07
79% 79%
-
EBIT (Operating Income) EBIT -42 -42
86% 86%
-
Net Profit -38 -38
70% 70%
-

In millions USD.

Don't miss a Thing! We will send you all news about Benitec Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Benitec Biopharma Inc Stock News

Neutral
GlobeNewsWire
about one hour ago
– Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301–
Positive
24/7 Wall Street
2 days ago
In the past week or so, beneficial owners Carl Icahn and Mario Gabelli made some big bets in Monro Inc.
Neutral
GlobeNewsWire
9 days ago
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten public offering of 5,930,000 share...
More Benitec Biopharma Inc News

Company Profile

Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The firms proprietary platforms includes DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on April 13, 2020 and is headquartered in Hayward, CA.

Head office United States
CEO Jerel Banks
Employees 16
Founded 2019
Website benitec.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today